Surrogates, substudies, and real clinical end points in trials of drug-eluting stents.
Publication
, Journal Article
Kereiakes, DJ; Kuntz, RE; Mauri, L; Krucoff, MW
Published in: J Am Coll Cardiol
April 19, 2005
Duke Scholars
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
April 19, 2005
Volume
45
Issue
8
Start / End Page
1206 / 1212
Location
United States
Related Subject Headings
- Stents
- Research Design
- Randomized Controlled Trials as Topic
- Paclitaxel
- Humans
- Coronary Restenosis
- Coronary Disease
- Clinical Trials, Phase IV as Topic
- Cardiovascular System & Hematology
- Antineoplastic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Kereiakes, D. J., Kuntz, R. E., Mauri, L., & Krucoff, M. W. (2005). Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol, 45(8), 1206–1212. https://doi.org/10.1016/j.jacc.2005.01.005
Kereiakes, Dean J., Richard E. Kuntz, Laura Mauri, and Mitchell W. Krucoff. “Surrogates, substudies, and real clinical end points in trials of drug-eluting stents.” J Am Coll Cardiol 45, no. 8 (April 19, 2005): 1206–12. https://doi.org/10.1016/j.jacc.2005.01.005.
Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005 Apr 19;45(8):1206–12.
Kereiakes, Dean J., et al. “Surrogates, substudies, and real clinical end points in trials of drug-eluting stents.” J Am Coll Cardiol, vol. 45, no. 8, Apr. 2005, pp. 1206–12. Pubmed, doi:10.1016/j.jacc.2005.01.005.
Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005 Apr 19;45(8):1206–1212.
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
April 19, 2005
Volume
45
Issue
8
Start / End Page
1206 / 1212
Location
United States
Related Subject Headings
- Stents
- Research Design
- Randomized Controlled Trials as Topic
- Paclitaxel
- Humans
- Coronary Restenosis
- Coronary Disease
- Clinical Trials, Phase IV as Topic
- Cardiovascular System & Hematology
- Antineoplastic Agents